Management of Dyssynergic Defecation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMayo Clinic

About this trial

The purpose of this research is to better understand constipation and improve biofeedback treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Men and women aged 18-80 years who are able and willing to provide written informed consent and to comply with the requirements for the entire study

Satisfy Rome III criteria for functional constipation and/or irritable bowel syndrome as assessed by questionnaires and objective evidence of dyssynergic defecation on anorectal testing

Disqualifiers

Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other diseases that may interfere with the objectives of the study and/or pose safety concerns.

History of total, hemi- or subtotal colectomy at any time or other abdominal operations within 60 days prior to entry into the study. Segmental resection of the colon (e.g. sigmoid resection) for diverticulitis will be permitted.

Current anal fissure

Clinically significant structural abnormalities (eg, rectocele > 4cm, large enterocele, full thickness rectal prolapse) that, in the opinion of the investigator, are likely contributing to symptoms

Trial design

Design model

Parallel

Treatments tested in this trial

  • Biofeedback

    Behavioral

    During anorectal biofeedback therapy, subjects are coached to improve abnormal patterns while observing activity recorded by manometry and/or surface EMG (electromyography) on a computer monitor while seated on a chair or a commode.

  • Inspiratory muscle training (IMT)

    Behavioral

    Subjects will engage in inspiratory muscle training (IMT) that is tailored to the baseline performance of the individual.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Biofeedback and inspiratory muscle training (BFT Plus)Experimental treatment 2 interventions
Group B: Biofeedback only (BFT Alone)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in rectoanal gradient during evacuation

Rectoanal gradient during evacuation is the pressure difference between the rectum and the anal canal during simulated evacuation, measured in millimeters of mercury (mmHg).

Time frame
Baseline, through study completion, an average of 16 weeks
2

Change in rectal pressure during evacuation

Rectal pressure during evacuation is the difference in rectal pressure during - before evacuation. Results are measured in millimeters of mercury (mmHg).

Time frame
Baseline, through study completion, an average of 16 weeks
3

Change in balloon expulsion time

Rectal balloon expulsion directly assesses evacuation. Patients will be asked to expel a rectal balloon inflated up to 50 ml of water. The time required to expel the balloon will be measured and reported in seconds.

Time frame
Baseline, through study completion, an average of 16 weeks
4

Change in rectal emptying time

Rectal emptying will be assessed via fecoflowmetry by measuring the time required to defecate (seconds) artificial stool from the rectum

Time frame
Baseline, through study completion, an average of 16 weeks

Secondary outcomes

1

Change in Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire

The PAC-SYM questionnaire assesses the severity of patient-reported symptoms related to constipation. The questionnaire is divided into three symptom subscales: abdominal (four items); rectal (three items); and stool (five items). Items are scored on 5-point Likert scales, with scores ranging from 0 to 4 (0 = 'symptom absent', 1 = 'mild', 2 = 'moderate', 3 = 'severe' and 4 = 'very severe'). A mean total score in the range of 0-4 is generated by dividing the total score by the number of questions completed; the lower the total score, the lower the symptom burden. Scores range from 0 to 48.

Time frame
Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion
2

Change in Patient Assessment of Constipation - Quality of Life (PAC-QOL) questionnaire

The PAC-QOL questionnaire is a patient-reported outcome measure to evaluate quality of life in constipated persons. The questionnaire is divided into four subscales: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items). Scale scores represent average item scores and range from 0 to 4, where higher scores represent poorer quality of life. Scores range from 0 to 112.

Time frame
Baseline, through study completion, an average of 16 weeks, 3 months post completion , 12 months post completion
3

Physical Activity Rating Scale

Physical Activity Rating is a questionnaire for categorizing physical activity level, which is used in the equation for the non-exercise fitness test. The Physical Activity Rating is a score value between 0 to 7. The non-exercise fitness test of VO2max, a measure of cardiovascular fitness, will be calculated using the following equation: 56.363 + 1.921 (Physical Activity Rating) - 0.381(Age) - 0.754(Body Mass Index) + 10.987(Sex: 0 for women, 1 for men)

Time frame
Baseline
4

Quebec User Evaluation of Satisfaction with Assistive Technology questionnaire

Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) 11-item questionnaire is a standardized tool to measure the satisfaction of an individual who is using an assistive device. It inquiries about the assistive device itself: dimensions, weight, ease of adjustment, safety, durability, ease of use, comfortability, and effectiveness; and service: service delivery, maintenance, professional services, and follow up services. Each question is answered on a Likert scale, where 1 = not satisfied at all, and 5 = very satisfied. Possible scores range from 11 to 55.

Time frame
through study completion, an average of 16 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.